HIF Solitude

Solitude Therapeutics is a preclinical-stage biotechnology company focused on developing novel small molecule therapies for metabolic and inflammatory diseases. The company's core technology centers on the modulation of Hypoxia-Inducible Factor 1 (HIF-1) signaling, a pathway recently identified as a key driver of metabolic dysfunction in adipose tissue. By inhibiting HIF-1α, Solitude aims to treat conditions such as obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis (MASH). The company was founded based on research from the Harvard T.H. Chan School of Public Health and is supported by prominent venture capital investors. Their lead programs are currently in the discovery and lead optimization phases, targeting the restoration of metabolic homeostasis.